Spyre Therapeutics, Inc.
SYRE Healthcare Biotechnology
Spyre Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $886,000.00, down 62.0% from fiscal 2022. In the quarter to June 2026, EPS grew 26.5% and free cash flow fell 50.1%, each against the same quarter a year earlier.
Follow SYRE
Spyre Therapeutics, Inc. (SYRE) EV/Sales
As of 16 October 2026, Spyre Therapeutics, Inc. (SYRE) trades at a EV/Sales of 5,336×. Over the past ten years it has ranged from −188× (February 2024) to 7,669× (August 2026); the current reading is higher than 97% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | −182× | — |
| FY2022 | −8.7× | — |
| FY2021 | 10.4× | (15.49%) |
| FY2018 | 12.3× | 105.63% |
| FY2017 | 6.0× | — |
| FY2016 | −4.1× | — |
| FY2015 | −3.3× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2023 | −182× | — |
| Jun 2023 | −157× | — |
| Mar 2023 | −9.6× | — |
| Dec 2022 | −8.7× | — |
| 19 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ABVX Abivax SA Sponsored ADR compare | n/m |
| IONS Ionis Pharmaceuticals, Inc. compare | 7.8× |
| TGTX TG Therapeutics, Inc. compare | 9.8× |
| AXSM Axsome Therapeutics, Inc. compare | 10.2× |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | 10.9× |
| IOVA Iovance Biotherapeutics, Inc. compare | 17.9× |
| PTGX Protagonist Therapeutics, Inc. compare | 27.4× |
| PRAX Praxis Precision Medicines, Inc. compare | 735× |
| SYRE Spyre Therapeutics, Inc. | 5,336× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)